Biotech Values

[DewDiligence]

TEVA NVS MNTA: So now you are saying Novartis did not need the data at all?

NVS sought out MNTA to develop a generic version of Copaxone. MNTA’s proprietary technology allows full characterization and reverse engineering of complex drugs such as Copaxone. So, yes, I’m emphatically stating that NVS did not need to steal Teva’s Copaxone data in order to develop a generic version of Copaxone in collaboration with MNTA.